Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series
Francesco Schettini(Target (United States)), Grazia Arpino(University of Naples Federico II), Carmine De Angelis(Baylor College of Medicine), Cinzia Cardalesi(University of Naples Federico II), Carmen G. Rea(University of Naples Federico II), Pierfrancesco Maione, Guglielmo Thomas(Clinica Mediterranea), Valeria Forestieri(University of Naples Federico II), Gennaro Limite(University of Naples Federico II), Mario Giuliano(Regione Campania), Martina Viggiani(Fribourg Development Agency), Sabino De Placido, Rossella Lauria, Luca Malorni(Azienda Usl Toscana Centro), Giuseppe Buono(Federico II University Hospital), Irene De Santo(University of Naples Federico II), Antonello Accurso(University of Naples Federico II)
Cited by 2
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282